Dimerix Limited provided an update on the CLARITY 2.0 study in COVID-19 patients in India. According to figures from Johns Hopkins University, India recorded more than 750,000 new cases over the weekend, bringing the cumulative total close to 23 million cases and 250,000 deaths across the country to date. Furthermore, the World Health Organization (WHO) has announced that the coronavirus variant first identified in India last year was being classified as a "variant of global concern.with some preliminary studies suggesting increased transmissibility." Following direct communications with Drug Controller General of India (DCGI - Indian regulatory authority), CLARITY 2.0 project management have been advised that as a result of the devastating wave affecting India, some DCGI and hospital staff are reported to have contracted COVID-19. Due to the significant number of COVID infections, some DCGI review meetings have been postponed and the final permit required for recruitment initiation of the CLARITY 2.0 study anticipated in April has been delayed. Pending DCGI meetings being resumed, all remaining site start up activities will be completed and sites are expected to start recruiting participants shortly. Advice will be provided when final approvals are received, and when dosing is to commence.